126 related articles for article (PubMed ID: 7610514)
1. [Principles of tumor invasion and metastasis].
Otto T; Goepel M; Recker F; Rübben H
Urologe A; 1995 May; 34(3):208-11. PubMed ID: 7610514
[TBL] [Abstract][Full Text] [Related]
2. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.
Otto T; Birchmeier W; Schmidt U; Hinke A; Schipper J; Rübben H; Raz A
Cancer Res; 1994 Jun; 54(12):3120-3. PubMed ID: 8205527
[TBL] [Abstract][Full Text] [Related]
3. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
4. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder.
Korman HJ; Peabody JO; Cerny JC; Farah RN; Yao J; Raz A
J Urol; 1996 Jan; 155(1):347-9. PubMed ID: 7490884
[TBL] [Abstract][Full Text] [Related]
5. Motility- and adhesion factors in bladder carcinoma.
Otto T; Goepel M; Enzwi SM; Meyer-Schwickerath M; Rübben H
Investig Urol (Berl); 1994; 5():80-4. PubMed ID: 7719326
[No Abstract] [Full Text] [Related]
6. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
7. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
8. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.
Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D
Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773
[TBL] [Abstract][Full Text] [Related]
9. Autocrine motility factor receptor: a clinical review.
Chiu CG; St-Pierre P; Nabi IR; Wiseman SM
Expert Rev Anticancer Ther; 2008 Feb; 8(2):207-17. PubMed ID: 18279062
[TBL] [Abstract][Full Text] [Related]
10. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
12. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
13. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers.
Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M
Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
15. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.
Lee JS; Leem SH; Lee SY; Kim SC; Park ES; Kim SB; Kim SK; Kim YJ; Kim WJ; Chu IS
J Clin Oncol; 2010 Jun; 28(16):2660-7. PubMed ID: 20421545
[TBL] [Abstract][Full Text] [Related]
16. A study of prognosis and clinicopathology of bladder cancer to blood group type of host patients in Japan.
Yamada T; Fukui I; Yokokawa M; Oshima H
Scand J Urol Nephrol; 1993; 27(2):199-203. PubMed ID: 8351472
[TBL] [Abstract][Full Text] [Related]
17. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene.
Sakano S; Berggren P; Kumar R; Steineck G; Adolfsson J; Onelöv E; Hemminki K; Larsson P
Int J Cancer; 2003 Mar; 104(1):98-103. PubMed ID: 12532425
[TBL] [Abstract][Full Text] [Related]
18. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
[TBL] [Abstract][Full Text] [Related]
19. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.
Wang W; Yang LY; Yang ZL; Peng JX; Yang JQ
Dig Dis Sci; 2007 Mar; 52(3):770-5. PubMed ID: 17265125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]